EP1567178A4 - Modulators of receptors for parathyrois hormone and parathyroid hormone-related protein - Google Patents

Modulators of receptors for parathyrois hormone and parathyroid hormone-related protein

Info

Publication number
EP1567178A4
EP1567178A4 EP02793926A EP02793926A EP1567178A4 EP 1567178 A4 EP1567178 A4 EP 1567178A4 EP 02793926 A EP02793926 A EP 02793926A EP 02793926 A EP02793926 A EP 02793926A EP 1567178 A4 EP1567178 A4 EP 1567178A4
Authority
EP
European Patent Office
Prior art keywords
hormone
parathyrois
modulators
receptors
related protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02793926A
Other languages
German (de)
French (fr)
Other versions
EP1567178A1 (en
Inventor
Paul Kostenuik
Colin V Gegg
Mark Anthony Jarosinski
Olaf Boris Kinstler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of EP1567178A1 publication Critical patent/EP1567178A1/en
Publication of EP1567178A4 publication Critical patent/EP1567178A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP02793926A 2002-11-01 2002-11-01 Modulators of receptors for parathyrois hormone and parathyroid hormone-related protein Withdrawn EP1567178A4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2002/036419 WO2004060386A1 (en) 2002-11-01 2002-11-01 Modulators of receptors for parathyrois hormone and parathyroid hormone-related protein

Publications (2)

Publication Number Publication Date
EP1567178A1 EP1567178A1 (en) 2005-08-31
EP1567178A4 true EP1567178A4 (en) 2009-07-15

Family

ID=32710245

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02793926A Withdrawn EP1567178A4 (en) 2002-11-01 2002-11-01 Modulators of receptors for parathyrois hormone and parathyroid hormone-related protein

Country Status (4)

Country Link
EP (1) EP1567178A4 (en)
AU (1) AU2002359391A1 (en)
CA (1) CA2511966A1 (en)
WO (1) WO2004060386A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003059291A2 (en) 2002-01-10 2003-07-24 Osteotrophin Llc Treatment of bone disorders with skeletal anabolic drugs
US20030191056A1 (en) * 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
MX2007015819A (en) * 2005-06-13 2008-02-22 Nastech Pharm Co Transmucosal delivery of peptide derivatives.
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
PE20070684A1 (en) 2005-11-14 2007-08-06 Amgen Inc RANKL-PTH / PTHrP ANTIBODY CHEMERICAL MOLECULES
US8288339B2 (en) 2006-04-20 2012-10-16 Amgen Inc. GLP-1 compounds
USRE49444E1 (en) 2006-10-03 2023-03-07 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
US7803770B2 (en) 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
PT2957278T (en) 2006-10-03 2017-08-23 Ipsen Pharma Sas A stable composition comprising pthrp and uses thereof
WO2008048784A1 (en) 2006-10-13 2008-04-24 Eli Lilly And Company Pegylated pth as pth receptor modulators and uses thereof
CA2782640A1 (en) 2009-12-07 2011-06-16 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
CN105431548A (en) 2013-03-15 2016-03-23 生物医学研究机构基金会 Method for the diagnosis, prognosis and treatment of cancer metastasis
IL297369B1 (en) 2015-04-29 2024-02-01 Radius Pharmaceuticals Inc Rad1901 for use in a method of treatmenet of mutant estrogen receptor positive breast cancer or a mutanat estrogen receptor positive ovarian cancer
KR102322802B1 (en) 2017-01-05 2021-11-04 래디어스 파마슈티컬스, 인코포레이티드 Polymorphic form of RAD1901-2HCL
US10996208B2 (en) 2017-04-28 2021-05-04 Radius Health, Inc. Abaloparatide formulations and methods of testing, storing, modifying, and using same
US11643385B2 (en) 2018-07-04 2023-05-09 Radius Pharmaceuticals, Inc. Polymorphic forms of RAD1901-2HCl

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993006846A1 (en) * 1991-10-10 1993-04-15 Pang Peter K T Parathyroid hormone analogues and use in osteoporosis treatment
WO1998005683A1 (en) * 1996-08-02 1998-02-12 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
WO2001081415A2 (en) * 2000-04-27 2001-11-01 Amgen Inc. Parathyroid hormone and parathyroid hormone-related protein antagonists
WO2002068459A2 (en) * 2001-02-21 2002-09-06 Clontech Laboratories, Inc. Non aggregating fluorescent proteins and methods for using the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589452A (en) * 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
DE69942035D1 (en) * 1998-11-25 2010-04-01 Gen Hospital Corp HUMAN PARATHYROIDHORMONE, MODIFICATIONS, MANUFACTURE AND USE

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993006846A1 (en) * 1991-10-10 1993-04-15 Pang Peter K T Parathyroid hormone analogues and use in osteoporosis treatment
WO1998005683A1 (en) * 1996-08-02 1998-02-12 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
WO2001081415A2 (en) * 2000-04-27 2001-11-01 Amgen Inc. Parathyroid hormone and parathyroid hormone-related protein antagonists
WO2002068459A2 (en) * 2001-02-21 2002-09-06 Clontech Laboratories, Inc. Non aggregating fluorescent proteins and methods for using the same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BARBIER JEAN-RENE ET AL: "Structure and activities of constrained analogues of human parathyroid hormone and parathyroid hormone-related peptide: Implications for receptor-activating conformations of the hormones", BIOCHEMISTRY, vol. 39, no. 47, 28 November 2000 (2000-11-28), pages 14522 - 14530, XP002530193, ISSN: 0006-2960 *
KINSTLER O ET AL: "Mono-N-terminal poly(ethylene glycol)-protein conjugates", ADVANCED DRUG DELIVERY REVIEWS 20020617 NL, vol. 54, no. 4, 17 June 2002 (2002-06-17), pages 477 - 485, XP002530194, ISSN: 0169-409X *
See also references of WO2004060386A1 *

Also Published As

Publication number Publication date
CA2511966A1 (en) 2004-07-22
WO2004060386A1 (en) 2004-07-22
AU2002359391A1 (en) 2004-07-29
EP1567178A1 (en) 2005-08-31

Similar Documents

Publication Publication Date Title
HUP0300465A3 (en) Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
EP1567178A4 (en) Modulators of receptors for parathyrois hormone and parathyroid hormone-related protein
AU2003278766A1 (en) Method and device for the controlled delivery of parathyroid hormone
AU2003251970A8 (en) Modulators of the glucocorticoid receptor and method
AU2003243497A8 (en) Antagonists of melanin concentrating hormone receptor
HK1072559A1 (en) Methods and dosage forms for controled delivery ofpaliperidone
AU2002353629A8 (en) Method and system for providing contents
EP1635872A4 (en) Antibodies and fusion proteins that include engineered constant regions
AU2002366384A8 (en) Insulin and igf-1 receptor agonists and antagonists
AU2003222704A1 (en) Method and device for dosing small volumes of liquid
HUP0301063A3 (en) Benzoic-acid isononylesters and applying them
AU2003251527A1 (en) Analogs of parathyroid hormone and pth-related protein as bone anabolic agents
EP1538190A4 (en) High-brightness mechanoluminescence material and method for preparing same
AU2003222225A8 (en) Receptors and membrane-associated proteins
IL175575A0 (en) Biomarkers for the efficacy of calcitionin and parathyroid hormone treatment
AU2002317094A1 (en) Apparatus for dispensing particulate material and components therefor
ZA200208518B (en) Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein.
AU2003245170A1 (en) Use of monocarboxylate transporter protein for thyroid hormone transport
AU2003262638A8 (en) Biotinylation of proteins
AU2003279779A1 (en) Methods and formulations comprising agonists and antagonists of nuclear hormone receptors
AU2003261986A1 (en) Device for liquid dilution and mixing
AU2003272799A8 (en) Receptors and membrane-associated proteins
PL359410A1 (en) Parathyroid hormone and parathyroid hormone-related protein antagonists
AU2003256666A8 (en) Impactor and paste feeder
AU2003295437A8 (en) Receptors and membrane-associated proteins

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050531

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KINSTLER, OLAF, BORIS

Inventor name: JAROSINSKI, MARK, ANTHONY

Inventor name: GEGG, COLIN, V.

Inventor name: KOSTENUIK, PAUL

A4 Supplementary search report drawn up and despatched

Effective date: 20090615

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090915